Coronavirus disease 2019(COVID-19),which was outbreak in December 2019 Wuhan,China,has spread to more than 100 countries.In addition to respiratory symptoms,COVID-19 can also cause some digestive symptoms such as naus...Coronavirus disease 2019(COVID-19),which was outbreak in December 2019 Wuhan,China,has spread to more than 100 countries.In addition to respiratory symptoms,COVID-19 can also cause some digestive symptoms such as nausea and diarrhea.As a variety of respiratory diseases which are associated with a dysbiosis in both airway microbiota and the intestinal microbiota,COVID-19 may cause digestive symptoms through a constant cross-talk between the system which is known as the Gut_Lung Axis.Additionally,lymphopenia and hypercytokinemia were also common in COVID-19 patients which suggest that COVID-19 could compromise the immune system.Given the fact that gut microbiota not only could maintain immune homeostasis and immune responses at local mucosal surfaces,but also has distal protective effects and protect against respiratory virus.FMT is an effective way to enhance immunity and would be a potential therapy for individuals with viral infection.However,currently no direct clinical evidence proved that modulation of gut microbiota has the therapeutic role in treatment of COVID-19,from the perspective of microbiota and immunity after viral infection,we speculate that targeting gut microbiota might be a new therapeutic option or at least adjuvant therapeutic choice.In this Personal View,we describe the five aspects:COVID-19 and compromised immunity system,Microbiota,immune system and viral infection,FMT,immunity and virus infection,potential application of FMT in the treatment of COVID-19.展开更多
Fecal microbiota transplantation(FMT)has been used in a wide variety of diseases.Many researchers hypothesize that the dysbiosis of intestinal microbiota plays an important role in the development of gut-derived infec...Fecal microbiota transplantation(FMT)has been used in a wide variety of diseases.Many researchers hypothesize that the dysbiosis of intestinal microbiota plays an important role in the development of gut-derived infections;thus,FMT is a potential therapeutic target against multiple organ dysfunction syndrome(MODS).A 106-year-old male patient was initially diagnosed with cerebral infarction and pulmonary infection.During the course of hospitalization,the patient developed MODS.The patient received a single nasogastric infusion of sterile-filtered,pathogen-free feces from a healthy donor.Fecal samples were collected every two days post-infusion to monitor changes in the microbiota composition in response to treatment.After FMT,MODS and severe diarrhea were alleviated;the patient’s fecal microbiome diversity resembled that of the healthy donor’s fecal microbiome;moreover,his clinical symptoms improved remarkably with the changes in fecal microbiome.Additionally,no observable side effects were noted during FMT treatment.These findings warrant further investigation of FMT as a putative new therapy for treating microbiota-related diseases,such as MODS.展开更多
基金This project was supported by National Natural Science foundation of China(81970156).We thank Bohong Dengand Fusheng Liu for assistance in preparing the manuscript.
文摘Coronavirus disease 2019(COVID-19),which was outbreak in December 2019 Wuhan,China,has spread to more than 100 countries.In addition to respiratory symptoms,COVID-19 can also cause some digestive symptoms such as nausea and diarrhea.As a variety of respiratory diseases which are associated with a dysbiosis in both airway microbiota and the intestinal microbiota,COVID-19 may cause digestive symptoms through a constant cross-talk between the system which is known as the Gut_Lung Axis.Additionally,lymphopenia and hypercytokinemia were also common in COVID-19 patients which suggest that COVID-19 could compromise the immune system.Given the fact that gut microbiota not only could maintain immune homeostasis and immune responses at local mucosal surfaces,but also has distal protective effects and protect against respiratory virus.FMT is an effective way to enhance immunity and would be a potential therapy for individuals with viral infection.However,currently no direct clinical evidence proved that modulation of gut microbiota has the therapeutic role in treatment of COVID-19,from the perspective of microbiota and immunity after viral infection,we speculate that targeting gut microbiota might be a new therapeutic option or at least adjuvant therapeutic choice.In this Personal View,we describe the five aspects:COVID-19 and compromised immunity system,Microbiota,immune system and viral infection,FMT,immunity and virus infection,potential application of FMT in the treatment of COVID-19.
文摘Fecal microbiota transplantation(FMT)has been used in a wide variety of diseases.Many researchers hypothesize that the dysbiosis of intestinal microbiota plays an important role in the development of gut-derived infections;thus,FMT is a potential therapeutic target against multiple organ dysfunction syndrome(MODS).A 106-year-old male patient was initially diagnosed with cerebral infarction and pulmonary infection.During the course of hospitalization,the patient developed MODS.The patient received a single nasogastric infusion of sterile-filtered,pathogen-free feces from a healthy donor.Fecal samples were collected every two days post-infusion to monitor changes in the microbiota composition in response to treatment.After FMT,MODS and severe diarrhea were alleviated;the patient’s fecal microbiome diversity resembled that of the healthy donor’s fecal microbiome;moreover,his clinical symptoms improved remarkably with the changes in fecal microbiome.Additionally,no observable side effects were noted during FMT treatment.These findings warrant further investigation of FMT as a putative new therapy for treating microbiota-related diseases,such as MODS.
